Paper · 17664483
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
Wick A and 9 others. J Clin Oncol, 2007. Cited by 211 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. Papers, record 17664483. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17664483
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Alkylating | Major topic |
| Brain Neoplasms | Major topic |
| Dacarbazine | Major topic |
| Glioma | Major topic |
| Adult | |
| DNA Methylation | |
| Disease Progression | |
| Drug Administration Schedule | |
| Female | |
| Humans | |
| Magnetic Resonance Imaging | |
| Male | |
| Middle Aged | |
| Neoplasm Recurrence, Local | |
| Polymerase Chain Reaction | |
| Prospective Studies | |
| Survival Analysis | |
| Temozolomide | |
| Treatment Outcome |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by109
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 211 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,334,687 | From relapse to survival: real-world clinical impact of a multimodal approach in first-time recurrent glioblastoma : FROST: multimodal treatment for GBM recurrence. | J Neurooncol | 2026 | https://conductscience.org/library/papers/42334687 | PubMed |
| 41,096,686 | Navigating the Central Nervous System (CNS): A Pharmacokinetic Approach to the Treatment of CNS Tumors, Glioblastoma Multiforme (GBM), in Particular. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41096686 | PubMed |
| 40,661,859 | Cisplatin and Alternating Temozolomide in Recurrent High-Grade Gliomas: Efficacy and the Role of Tumor-Infiltrating Lymphocytes in a Phase II Clinical Trial. | Clin Med Insights Oncol | 2025 | https://conductscience.org/library/papers/40661859 | PubMed |
| 40,653,575 | Effectiveness of Gamma Knife radiosurgery for recurrent glioblastoma: a 10-year retrospective analysis. | Neurosurg Rev | 2025 | https://conductscience.org/library/papers/40653575 | PubMed |
| 40,319,068 | Therapy-induced senescence of glioblastoma cells is determined by the p21CIP1-CDK1/2 axis and does not require activation of DREAM. | Cell Death Dis | 2025 | https://conductscience.org/library/papers/40319068 | PubMed |
| 36,483,042 | Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study. | Front Oncol | 2022 | https://conductscience.org/library/papers/36483042 | PubMed |
| 34,771,532 | Enhancing T Cell Chemotaxis and Infiltration in Glioblastoma. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34771532 | PubMed |
| 33,863,808 | Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33863808 | PubMed |
| 33,785,481 | Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33785481 | PubMed |
| 32,813,186 | Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor. | J Neurooncol | 2021 | https://conductscience.org/library/papers/32813186 | PubMed |
1 to 10 of 109
See all 109 cited byGenes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MGMT | 4,255 | PubTator's text mining | https://conductscience.org/library/genes/4255 |
Source NCBI Gene
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17664483
GET https://conductscience.org/api/papers/v1/17664483/cited_by?page=2